Physicochemical pharmacokinetics as an optimization tool for generic development: A case study

    loading  Checking for direct PDF access through Ovid


In spite of the fact that dissolution time profiles of 250 mg ursodeoxycholic acid (UCDA) capsules developed by Sponsor and 250 mg hard capsules produced by Ursofalk®, Dr. Falk Pharma GmbH, indicated similarity (f2 = 60.6), a bioavailability study indicated unexpected differences in the formulations. To find an explanation of the in vivo performance of the compared formulations, the dissolution profiles were analyzed using a novel dissolution theory considering:

The dissolution model was applied to the measured data using SADAPT. Despite Cmax and AUC values showing higher values after administration of the test product, a reduction of UDCA particle size for the test formulation was suggested for reformulation. The decision was based on the strongly pH-dependent UDCA solubility, formation of insoluble crystals at low pH condition and the known high pH fluctuations ranging from pH 1 to 8 in empty stomach.

The performed reformulation led to increased dissolution rate of the test product and to a positive bioequivalence study which compared the reformulated test generic formulation with two reference products purchased from two highly regulated markets.

Related Topics

    loading  Loading Related Articles